Abiomed, Inc. (ABMD) Upgraded by Zacks to OUTPERFORM

Zacks Zacks Investment Research upgraded shares of Abiomed, Inc. (ABMD) from NEUTRAL to OUTPERFORM on May 28, 2013, with a target price of $26.00.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

To get a free copy of the research report on Abiomed, Inc. (ABMD),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .

Be the first to comment

Leave a Reply